Sister Mary Joseph's nodule (SMJN) is an umbilical mass referring to an intraabdominal and/or pelvic tumor's metastasis. SMJN is frequently associated with gynecological malignancies, but only 30 cases of SMJN originated from endometrial cancer have been described in the literature. We reported a case of SMJN detected within the primary diagnosis of endometrial cancer, in which a 1-year vaginal relapse occurs. A robotic single-site total hysterectomy and a bilateral salpingo-oophorectomy were performed to treat the primary tumor, followed by an adjuvant radiotherapy. The SMJN was resected during the surgical procedure. The relapse was treated by a partial colpectomy. No evidence of disease has been observed to date, and an overall survival of 31 months has been achieved. Due to the rare occurrence of an umbilical metastasis from an endometrial carcinoma, SMJN is difficult to recognize in this contest; nevertheless, its diagnosis is becoming increasingly important in relation to the choice of a proper treatment.
INTRODUCTION
Sister Mary Joseph's nodule (SMJN) is an umbilical mass referring to an intraabdominal and/or pelvic tumor's metastasis. It is a very rare condition: its incidence is about 1%-3% of all intraabdominal or pelvic malignancies and epidemiological studies revealed that this condition is predominant in women. [1] About 28% of all SMJN cases reported in the literature are associated with gynecological tumors, most commonly ovarian cancer, rarely endometrial cancer. [1] SMJN could show up within a broad spectrum of different manifestations; it varies from a soft, painless nodule to a hard ulcerated painfully mass. The presence of SMJN is not always easy to diagnose at a physical examination: The skin overlying the lesion can be normal, erythematous, or ulcerated and the nodule's diameter could reach 10 cm, even if its mean value is usually 2-3 cm. [2] The presence of SMJN is associated with a poor prognosis and an overall survival (OS) of 2-11 months from the initial diagnosis; [3] therefore, it is an important prognostic factor to take into account during patient's assessment.
In this report, we describe the clinical case of endometrial cancer occurs within a SMJN as a primary manifestation of this malignancy, with a relapse after primary tumor's treatment.
CASE REPORT
An 80-year-old multiparous female (body mass index = 27.4 kg/m 2 ) affected by hypertensive disorder referred to our National Cancer Centre in February 2015 for a 4-month history of vaginal bleeding. The bimanual gynecological examination revealed an enlarged uterus. Transvaginal ultrasonography revealed a uterine mass with a deep myometrial invasion. The hysteroscopy examination confirmed the presence of a mass in the endometrial cavity. The histological examination of the biopsy performed on this lesion showed an endometrial endometrioid carcinoma (EEC). The computed tomography of the chest, abdomen, and pelvis revealed a uterine mass, no lymph nodes metastasis and an umbilical nodule suspected of metastatic disease. Robotic single-site type A total hysterectomy, according to Querleau-
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This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. Morrow classification, [4] bilateral salpingo-oophorectomy and resection of the umbilical nodule were performed. Definitive histological examination showed an EEC poorly differentiated with neuroendocrine aspects, myometrial invasion >50%, linfovascular space invasion, and cervical stroma's invasion [ Figure 1a ]. The nodule was identified as a metastasis from EEC (SMJN) [ Figure 1b ]. The disease was classified according to the "International Federation of Gynecologists and Obstetricians" as IVB. [5] Due to the age and the clinical condition of our patient, surgery was followed only by pelvic external radiotherapy. After adjuvant radiation treatment, no symptoms or imaging examination's results were suspicious for a malignancy recurrence.
In September 2016, the patient was admitted to our hospital again for vaginal bleeding during the last month. A magnetic resonance imaging was performed; a 4 cm × 4.2 cm nodule in the vaginal cuff was detected, with no evidence for a cleavage plan from the rectum and the bladder. A positron emission tomography image was also performed: The presence of a vaginal nodule on the right side was confirmed without metastases at distant. The patient underwent partial colpectomy to remove the lesion. The histopathological examination revealed a relapse of endometrial cancer. After surgery, a vaginal brachytherapy was performed. At present, after 35 months from diagnosis, our patient has no evidence of disease (NED).
DISCUSSION
We reported a rare case of SMJN occurring within the primary diagnosis of endometrial cancer, treated by an excision during a robotic single-site total hysterectomy with salpingo-oophorectomy and a subsequent pelvic radiotherapy. The patient had a vaginal recurrence after 19 months from the initial diagnosis, treated by a partial colpectomy and a vaginal brachytherapy. At the time of the last oncological follow-up, the patient had no evidence of disease, with an OS of 35 months.
Metastatic umbilical nodule was first described in the literature in 1864. [6] The three most common primary sites, reported in literature, in women were found to be the ovary (range, 14%-41%), the endometrium (range, 1%-10%), and the pancreatobiliary tree (12%). [7, 8] The exact mechanism for the umbilical metastasis location is not clear. There are two main potential explanatory hypotheses: a direct spread of the tumor cells, which is the most common or a vascular and lymphatic spread. The direct peritoneal spread is enhanced by the multiple peritoneal folds, such as the umbilical ligament and ligamentum teres. [8] An early histologic diagnosis of this malignancy is very important since even if there is no treatment guideline, therefore, therapy usually consists of b a 
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Giner Galvañ et al. [9] surgical hysterectomy with bilateral salpingo-oophorectomy and a subsequent chemotherapy.
An umbilical tumor from endometrial cancer is extremely rare. Galvan reviewed 407 umbilical tumor cases, and 24 (5.9%) umbilical metastases cases were found among woman with uterine malignancy. [9] We reviewed the literature regarding all the cases of a SMJN related to endometrial cancer. At present, 30 cases of SMJN originating from endometrial carcinoma have been reported in the literature [ Table 1 ]. [1, 3, [10] [11] [12] [13] Moreover, Hertel et al. [14] and Ivanova et al. [15] described two cases of endometrial cancer, followed by umbilical relapses. In all these cases so, few information are available about tumor management, and chemotherapy was the most used adjuvant treatment.
We describe the SMJN related to the EC with the longest follow-up reported in literature (35 months). In our case, the SMJN was the only site of metastatic disease of endometrial cancer, probably due to direct peritoneal spread even if prove this is very difficult. Due to the age and the clinical condition of our patient, surgery was followed only by external radiotherapy of the pelvis and not by chemotherapy. Certainly, the primary tumor was followed by pelvic relapse and new surgery and brachytherapy were performed. However, our management of this tumor results in a disease-free survival of 19 months and an OS of 35 months. In our case, the presence of SMJN is indicative of a metastatic and aggressive disease, and this kind of association is very important during the assessment of patient's follow-up and treatment.
CONCLUSION
Due to the rare occurrence of an umbilical metastasis from an endometrial carcinoma, SMJN is difficult to recognize in this contest; nevertheless, its diagnosis is becoming increasingly important in relation to the choice of a proper treatment.
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